Evidence map›Paper›PMID 39272926›Full record

ReviewCancers2024

Aberrant SWI/SNF Complex Members Are Predominant in Rare Ovarian Malignancies-Therapeutic Vulnerabilities in Treatment-Resistant Subtypes.

Yue Ma, Natisha R Field, Tao Xie, Sarina Briscas, Emily G Kokinogoulis, Tali S Skipper, Amani Alghalayini, Farhana A Sarker, Nham Tran, Nikola A Bowden and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yue MaTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0002-1107-7789
Natisha R FieldTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0009-0004-6724-6360
Tao XieTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0002-0580-6877
Sarina BriscasTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Emily G KokinogoulisTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Tali S SkipperTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0009-0007-6313-761X
Amani AlghalayiniTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0002-2308-0256
Farhana A SarkerTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0009-0003-0990-1796
Nham TranSchool of Biomedical Engineering, Faculty of Engineering and IT, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Nikola A BowdenDrug Repurposing and Medicines Research Program, Hunter Medical Research Institute, Newcastle, NSW 2289, Australia.ORCID 0000-0002-6047-1694
Kristie-Ann DicksonTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0001-7307-8982
Deborah J MarshTranslational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia.ORCID 0000-0001-5899-4931

Funding

Australian Government Research Training Program not applicableAustralian Medical Research Future Fund 1199620Cancer Council New South Wales 2019/TPG1002Chinese Scholarship Council not applicableHunter Medical Research Institute Vanessa McGuigan Memorial Fellowship not applicableNational Health and Medical Research Council 2019296
6 · The paper itself

Abstract

SWI/SNF (SWItch/Sucrose Non-Fermentable) is the most frequently mutated chromatin-remodelling complex in human malignancy, with over 20% of tumours having a mutation in a SWI/SNF complex member. Mutations in specific SWI/SNF complex members are characteristic of rare chemoresistant ovarian cancer histopathological subtypes. Somatic mutations in

Indexed as

ARID1AARID1BBAF chromatin-remodelling complexendometrioid ovarian cancer (EnOC)endometriosishypercalcaemic type (SCCOHT)ovarian clear cell carcinoma (OCCC)Small cell carcinoma of the ovarySMARCA2SMARCA4SWI/SNF chromatin-remodelling complex

Identifiers

PMID39272926
PMCPMC11393890

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.